Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01156311 · ClinicalTrials.gov registry record · Phase 2
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT01156311 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 108 participants.
The verdict
NCT01156311, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting multiple sclerosis (RRMS).
Interventions
- DRUG dimethyl fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01156311
The ClinicalTrials.gov registry entry for NCT01156311 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dimethyl fumarate is the first listed.
NCT01156311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01156311 about?
NCT01156311 is a clinical study titled "BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis". The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting multiple sclerosis (RRMS).
What is the current status of trial NCT01156311?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2010-06. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01156311?
The interventions under investigation include: dimethyl fumarate (DRUG).
Who is sponsoring clinical trial NCT01156311?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.